BGLC (BioNexus Gene Lab) Total Debt per Share: $0.09 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLC BioNexus Gene Lab Corp BGLC
57 GF Score
Price $1.58
GF Value $2.14
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is BioNexus Gene Lab Total Debt per Share?

BioNexus Gene Lab BGLC +0.64% 57 Total Debt per Share is $0.09 as of Mar. 2026. GuruFocus rates BGLC with a GF Score™ of 57/100 and a GF Value™ of $2.14 (Modestly Undervalued). The stock has 6 warning signs investors should review.

$0.09 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. BioNexus Gene Lab's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.09.

BioNexus Gene Lab Total Debt per Share Historical Data

* Premium members only.

The historical data trend for BioNexus Gene Lab's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNexus Gene Lab Total Debt per Share Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.05 0.04 0.08 0.12 0.07

BioNexus Gene Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.11 0.10 0.07 0.09
BGLC
57GF Score
BioNexus Gene Lab Corp BGLC
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNexus Gene Lab Total Debt per Share Calculation

BioNexus Gene Lab's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.12+0.06)/2.42
=0.07

BioNexus Gene Lab's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.15+0.07)/2.42
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.09 mean?
BioNexus Gene Lab (BGLC) has a Total Debt per Share of $0.09 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's Total Debt per Share too high?
BioNexus Gene Lab's current Total Debt per Share is $0.09. Overall, BioNexus Gene Lab has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Total Debt per Share compare to VYST and QGAI?
BioNexus Gene Lab's Total Debt per Share of $0.09 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Chemicals company?
A good Total Debt per Share depends on the Chemicals industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Total Debt per Share is $0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.14, compared to a current price of $1.58 — trading 26.2% below its estimated fair value. The current Total Debt per Share is $0.09. BioNexus Gene Lab's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Total Debt per Share is $0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNexus Gene Lab (BGLC) Overvalued in 2026?

Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued. The current stock price of $1.58 is trading 26.2% below its estimated GF Value™ of $2.14. GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.

Key valuation signals for BGLC:

  • Total Debt per Share: $0.09
  • GF Value™: $2.14 vs. price of $1.58 (26.2% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNexus Gene Lab Business Description

Address No.5 Jln Bangsar Utama 1, Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
57GF Score

Get the complete analysis for BGLC

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.58
Price
$2.14
GF Value